OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate Cancer

December 2nd 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.

Dr. Carey on Ongoing Progress in HER2+ Breast Cancer

December 2nd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the ongoing progress with agents in development for the potential treatment of patients with HER2-positive breast cancer.

Dr. Antonia on Emerging Immunotherapies in Lung Cancer

December 2nd 2016

Scott J. Antonia, MD, PhD, chair of the Department of Thoracic Oncology at Moffit Cancer Center, discusses immunotherapies that are emerging in the field of lung cancer.

Dr. Dimosthenis on Prognosis Factors in Ewing Sarcoma

December 2nd 2016

Dimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognosis factors in patients with Ewing sarcoma.

Dr. Jahanzeb on Challenges in Non-Driver Adenocarcinoma

December 1st 2016

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the challenges researchers must overcome in patients with non-driver adenocarcinoma.

Dr. Hart on Advances in ALK+ NSCLC

December 1st 2016

Lowell L. Hart, MD, scientific director of Research at Florida Cancer Specialists & Research Institute, and associate professor of Internal Medicine at Wake Forest School of Medicine, discusses the recent advances in the area of ALK-positive non–small cell lung cancer.

Dr. Reardon on the Need for a New Standard of Care in GBM

December 1st 2016

David A. Reardon, MD, clinical director at the Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the need for a new standard of care in the treatment landscape of glioblastoma multiforme.

Dr. Wierda on Factors to Consider in Frontline Management of CLL

December 1st 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses factors that physicians should take into account when administering frontline treatment options to patients with chronic lymphocytic leukemia.

Dr. Mirza on Impact of Niraparib in Ovarian Cancer

November 30th 2016

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses niraparib in patients with platinum-sensitive recurrent ovarian cancer

Dr. Iyer on Evolving Treatments in Bladder Cancer

November 30th 2016

Gopa Iyer, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy options for patients with bladder cancer, but mentions how other agents are evolving the landscape. Iyer shared this insight during the 2016 OncLive® State of the Science Summit on Genitourinary Cancers.

Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer

November 30th 2016

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Margulis on Different Approaches to Adjuvant Therapy in RCC

November 30th 2016

Vitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.

Dr. Eytan Stein on Novel Combinations in AML

November 29th 2016

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the potential combinations that could be explored with novel agents in the treatment of patients with acute myeloid leukemia.

Dr. Tanios Bekaii-Saab on Sequencing Questions in mCRC

November 29th 2016

Tanios Bekaii-Saab, MD, a professor of Medicine at Mayo Clinic, discusses sequencing regorafenib (Stivarga) and TAS-102 (Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

November 29th 2016

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

Dr. Birrer on Remaining Challenges in Cervical Cancer

November 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.

Dr. Marshall on the Safety Profile of Y-90 in Colorectal Cancer

November 29th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the safety profile of Yttrium-90, particularly when combined with capecitabine as a treatment for patients with liver-dominant metastatic colorectal cancer.

Dr. Rathkopf on Investigative Agents in Prostate Cancer

November 28th 2016

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses agents being explored as treatments for patients with prostate cancer, including apalutamide and PARP inhibitors.

Dr. Sandler on Chemotherapy Combination Regimens in Prostate Cancer

November 28th 2016

Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.

Dr. Abida on Choosing Between Chemotherapy and Targeted Agents for Patients With Prostate Cancer

November 24th 2016

Wassim Abida, MD, PhD, assistant member and assistant attending physician in the Genitourinary Oncology Program at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with prostate cancer.